{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:10:38Z","timestamp":1784671838640,"version":"3.55.0"},"reference-count":123,"publisher":"Weston Medical Publishing","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Opioid Management"],"abstract":"<jats:p>We present data showing that the urinary metabolic ratio (MR) of metabolite to parent drug can be used to estimate the drug\u2013drug interactions (DDIs) of pain management and substance abuse treatment medications with other coadministered drugs. We quantitatively measure 18 drugs and their phase I metabolites and monitor the effects of 14 interfering drugs on their MRs. The 18 drugs include dextromethorphan, oxycodone, hydrocodone, tramadol, morphine, buprenorphine, fentanyl, clonazepam, alprazolam, quetiapine, carisoprodol, tapentadol, ketamine, methadone, impramine, and amitriptyline. The 14 interfering drugs include fluoxetine, paroxetine, bupropion, citalopram, sertraline, venlafaxine, duloxetine, risperidone, trazodone, aripiprazole, cyclobenzaprine, amphetamine, and tetrahydrocannabinol. Some of these interfering drugs are inhibitors of either the CYP2D6, CYP3A4\/5, or CYP2C19 pathways. By using the urinary MR of metabolite\/parent drug, we observed patterns of inhibition and enhancement due to DDIs. Using the MR reference intervals of the 18 drug pairs established in an earlier study, and the current DDI system, we can alert providers of unusual metabolism caused by DDIs. This will help providers do better prescribing or review more closely all medications and supplements patients are taking, thus avoiding underdosing or potential medication adverse reactions.<\/jats:p>","DOI":"10.5055\/jom.0907","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:16:10Z","timestamp":1753715770000},"page":"41-68","source":"Crossref","is-referenced-by-count":2,"title":["Urinary metabolic ratio of pain management and substance abuse treatment drugs: Drug\u2013drug interactions"],"prefix":"10.5055","volume":"21","author":[{"given":"Agnes","family":"Cua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Wickett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3748-9703","authenticated-orcid":false,"given":"Amadeo J.","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3008","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"96439","unstructured":"Karan L, McCance-Katz E: Pharmacokinetics. In Kosten TR, Gorelick D, Fiellin D (eds.): Principles of Addiction Medicine. Philadelphia, PA: Lippincott Willians & Wilkins, 2008: 67-84."},{"key":"96440","unstructured":"FDA: Drug interactions, what you should know. Available at https:\/\/www.fda.gov\/drugs\/resources-drugs\/drug-interactionswhat-you-should-know. Accessed October 3, 2024."},{"key":"96441","doi-asserted-by":"crossref","unstructured":"L\u00e9tinier L, Cossin S, Mansiaux Y, et al.: Risk of drug\u2013drug interactions in out-hospital drug dispensings in France: Results from the drug\u2013drug interaction prevalence study. Front Pharmacol. 2019; 10: 265. DOI: 10.3389\/fphar.2019.00265.","DOI":"10.3389\/fphar.2019.00265"},{"key":"96442","doi-asserted-by":"crossref","unstructured":"Crewe HK, Lennard MS, Tucker GT, et al.: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992; 34(3): 262-265. DOI: 10.1111\/j.1365-2125.1992.tb04134.x.","DOI":"10.1111\/j.1365-2125.1992.tb04134.x"},{"key":"96443","doi-asserted-by":"crossref","unstructured":"Kobayashi K, Yamamoto T, Chiba K, et al.: The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4\u2019-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol. 1995; 40(5): 481-485. DOI: 10.1111\/j.1365-2125.1995.tb05793.x.","DOI":"10.1111\/j.1365-2125.1995.tb05793.x"},{"key":"96444","doi-asserted-by":"crossref","unstructured":"Schmider J, Greenblatt DJ, von Moltke LL, et al.: Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: Studies of phenytoin p-hydroxylation. Br J Clin Pharmacol. 1997; 44(5): 495-498. DOI: 10.1046\/j.1365-2125.1997.00601.x.","DOI":"10.1046\/j.1365-2125.1997.00601.x"},{"key":"96445","doi-asserted-by":"crossref","unstructured":"Kotlyar M, Brauer LH, Tracy TS, et al.: Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol. 2005; 25(3): 226-229. DOI: 10.1097\/01.jcp.0000162805.46453.e3.","DOI":"10.1097\/01.jcp.0000162805.46453.e3"},{"key":"96446","unstructured":"Mayo Clinic: Fluoxetine (oral route). 2024. Available at https:\/\/www.mayoclinic.org\/drugs-supplements\/fluoxetine-oral-route\/description\/drg-20063952. Accessed October 3, 2024."},{"key":"96447","unstructured":"MedlinePlus: Citalopram. 2024. Available at https:Medlineplus.gov\/druginfo\/meds\/a699001.html. Accessed October 3, 2024."},{"key":"96448","doi-asserted-by":"crossref","unstructured":"Ball SE, Ahern D, Scatina J, et al.: Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol. 1997; 43(6): 619-626. DOI: 10.1046\/j.1365-2125.1997.00591.x.","DOI":"10.1046\/j.1365-2125.1997.00591.x"},{"key":"96449","doi-asserted-by":"crossref","unstructured":"von Moltke LL, Duan SX, Greenblatt DJ, et al.: Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. Biol Psychiatry. 1997; 41(3): 377-380. DOI: 10.1016\/s0006-3223(96)00406-4.","DOI":"10.1016\/S0006-3223(96)00406-4"},{"key":"96450","doi-asserted-by":"crossref","unstructured":"Skinner MH, Kuan HY, Pan A, et al.: Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther. 2003; 73(3): 170-177. DOI: 10.1067\/mcp.2003.28.","DOI":"10.1067\/mcp.2003.28"},{"key":"96451","unstructured":"FDA: Cymbalta (duloxetine hydrochloride) delayed-release capsule (package insert). 2007. Available at chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/ https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022516lbl.pdf. Accessed April 1, 2025."},{"key":"96452","doi-asserted-by":"crossref","unstructured":"von Moltke LL, Greenblatt DJ, Grassi JM, et al.: Citalopram and desmethylcitalopram in vitro: Human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999; 46(6): 839-849. DOI: 10.1016\/s0006-3223(98)00353-9.","DOI":"10.1016\/S0006-3223(98)00353-9"},{"key":"96453","doi-asserted-by":"crossref","unstructured":"Amchin J, Zarycranski W, Taylor KP, et al.: Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol. 1999; 39(3): 297-309.","DOI":"10.1177\/009127009903900314"},{"key":"96454","doi-asserted-by":"crossref","unstructured":"Nickley J, Kain J, Krock K, et al.: Severe drug\u2013drug interactions: Reported and missed. J Clin Toxicol. 2019; 9: 406. DOI: 10.4172\/2161-0495.10003406.","DOI":"10.4172\/2161-0495.1000406"},{"key":"96455","doi-asserted-by":"crossref","unstructured":"Knadler MP, Lobo E, Chappell J, et al.: Duloxetine: Clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011; 50(5): 281-294. DOI: 10.2165\/11539240-000000000-00000.","DOI":"10.2165\/11539240-000000000-00000"},{"key":"96456","doi-asserted-by":"crossref","unstructured":"Schadel M, Wu D, Otton SV, et al.: Pharmacokinetics of dextromethorphan and metabolites in humans: Influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol. 1995; 15(4): 263-269. DOI: 10.1097\/00004714-199508000-00005.","DOI":"10.1097\/00004714-199508000-00005"},{"key":"96457","doi-asserted-by":"crossref","unstructured":"Jurica J, Bartecek R, Zourkova A, et al.: Serum dextromethorphan\/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice. J Clin Pharm Ther. 2012; 37(4): 486-490. DOI: 10.1111\/j.1365-2710.2012.01333.x.","DOI":"10.1111\/j.1365-2710.2012.01333.x"},{"key":"96458","doi-asserted-by":"crossref","unstructured":"Coates S, Lazarus P: Hydrocodone, oxycodone, and morphine metabolism and drug\u2013drug interactions. J Pharmacol Exp Ther. 2023; 387(2): 150-169. DOI: 10.1124\/jpet.123.001651.","DOI":"10.1124\/jpet.123.001651"},{"key":"96459","unstructured":"Elsevier: Gold standard drug database, integrated database and clinical support engine. 2024. Available at https:\/\/www.elsevier.com\/products\/gold-standard-drug-database. Accessed October 3, 2024."},{"key":"96460","unstructured":"Shad M, Preskorn S: Antidepressants. In Metabolic Drug Interactions. Philadelphia, PA: Lippincott Williams & Wilkins, 2000: 563-577."},{"key":"96461","doi-asserted-by":"crossref","unstructured":"Krock K, Pesce A, Ritz D, et al.: Lower cutoffs for LC-MS\/MS urine drug testing indicates better patient compliance. Pain Phys. 2017; 7(7): E1107-E1113.","DOI":"10.36076\/ppj\/2017.7.E1107"},{"key":"96462","unstructured":"Pesce AJ, Chandler N, Ackerman G: Information technology structure for urine drug testing reports. 21st Century Pathol. 2021; 1(1): 103."},{"key":"96463","unstructured":"Pesce A, Sundyhanata R, Ritz D, et al.: Effects of a pandemic and isolation on alcohol and psychoactive medication use in a population of rehabilitation and pain patients. Ann Clin Lab Sci. 2021; 51(5): 694-697."},{"key":"96464","doi-asserted-by":"crossref","unstructured":"Strauch K, Lutz U, Bittner N, et al.: Dose\u2013response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles. Food Chem Toxicol. 2009; 47(8): 1928-1935. DOI: 10.1016\/j.fct.2009.05.004.","DOI":"10.1016\/j.fct.2009.05.004"},{"key":"96465","unstructured":"Yu A, Dong H, Lang D, et al.: Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab Dispos. 2001; 29(11): 1362-1365."},{"key":"96466","doi-asserted-by":"crossref","unstructured":"Lalovic B, Phillips B, Risler LL, et al.: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004; 32(4): 447-454. DOI: 10.1124\/dmd.32.4.447.","DOI":"10.1124\/dmd.32.4.447"},{"key":"96467","doi-asserted-by":"crossref","unstructured":"Otton SV, Schadel M, Cheung SW, et al.: CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther. 1993; 54(5): 463-472. DOI: 10.1038\/clpt.1993.177.","DOI":"10.1038\/clpt.1993.177"},{"key":"96468","unstructured":"Subrahmanyam V, Renwick AB, Walters DG, et al.: Identification of cytochrome P-450 isoforms responsible for cistramadol metabolism in human liver microsomes. Drug Metab Dispos. 2001; 29(8): 1146-1155."},{"key":"96469","doi-asserted-by":"crossref","unstructured":"Cone EJ, Heit HA, Caplan YH, et al.: Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol. 2006; 30(1): 1-5. DOI: 10.1093\/jat\/30.1.1.","DOI":"10.1093\/jat\/30.1.1"},{"key":"96470","doi-asserted-by":"crossref","unstructured":"Wasan AD, Michna E, Janfaza D, et al.: Interpreting urine drug tests: Prevalence of morphine metabolism to hydromorphone in chronic pain patients treated with morphine. Pain Med. 2008; 9(7): 918-923. DOI: 10.1111\/j.1526-4637.2007.00354.x.","DOI":"10.1111\/j.1526-4637.2007.00354.x"},{"key":"96471","doi-asserted-by":"crossref","unstructured":"Picard N, Cresteil T, Djebli N, et al.: In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways. Drug Metab Dispos. 2005; 33(5): 689-695. DOI: 10.1124\/dmd.105.003681.","DOI":"10.1124\/dmd.105.003681"},{"key":"96472","unstructured":"Labroo RB, Paine MF, Thummel KE, et al.: Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos. 1997; 25(9): 1072-1080."},{"key":"96473","doi-asserted-by":"crossref","unstructured":"Hutchinson MR, Menelaou A, Foster DJR, et al.: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004; 57(3): 287-297. DOI: 10.1046\/j.1365-2125.2003.02002.x.","DOI":"10.1046\/j.1365-2125.2003.02002.x"},{"key":"96474","doi-asserted-by":"crossref","unstructured":"T\u00f3th K, Csukly G, Sirok D, et al.: Optimization of clonazepam therapy adjusted to patient\u2019s CYP3A status and NAT2 genotype. Int J Neuropsychopharmacol. 2016; 19(12): pyw083. DOI: 10.1093\/ijnp\/pyw083.","DOI":"10.1093\/ijnp\/pyw083"},{"key":"96475","doi-asserted-by":"crossref","unstructured":"Gorski JC, Jones DR, Hamman MA, et al.: Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica. 1999; 29(9): 931-944. DOI: 10.1080\/004982599238173.","DOI":"10.1080\/004982599238173"},{"key":"96476","doi-asserted-by":"crossref","unstructured":"Grimm SW, Richtand NM, Winter HR, et al.: Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006; 61(1): 58-69. DOI: 10.1111\/j.1365-2125.2005.02507.x.","DOI":"10.1111\/j.1365-2125.2005.02507.x"},{"key":"96477","doi-asserted-by":"crossref","unstructured":"DeVane CL, Nemeroff CB: Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet. 2001; 40(7): 509-522. DOI: 10.2165\/00003088-200140070-00003.","DOI":"10.2165\/00003088-200140070-00003"},{"key":"96478","doi-asserted-by":"crossref","unstructured":"Dal\u00e9n P, Alvan G, Wakelkamp M, et al.: Formation of meprobamate from carisoprodol is catalysed by CYP2C19. Pharmacogenetics. 1996; 6(5): 387-394. DOI: 10.1097\/00008571-199610000-00002.","DOI":"10.1097\/00008571-199610000-00002"},{"key":"96479","doi-asserted-by":"crossref","unstructured":"Terlinden R, Kogel BY, Englberger W, et al.: In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol. 2010; 32(1): 31-38. DOI: 10.1358\/mf.2010.32.1.1434165.","DOI":"10.1358\/mf.2010.32.1.1434165"},{"key":"96480","doi-asserted-by":"crossref","unstructured":"Hijazi Y, Boulieu R: Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos Biol Fate Chem. 2002; 30(7): 853-858. DOI: 10.1124\/dmd.30.7.853.","DOI":"10.1124\/dmd.30.7.853"},{"key":"96481","doi-asserted-by":"crossref","unstructured":"Ahmad T, Valentovic MA, Rankin GO: Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics. Biochem Pharmacol. 2018; 153: 196-204. DOI: 10.1016\/j.bcp.2018.02.020.","DOI":"10.1016\/j.bcp.2018.02.020"},{"key":"96482","doi-asserted-by":"crossref","unstructured":"Lemoine A, Gautier JC, Azoulay D, et al.: Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol. 1993; 43(5): 827-832.","DOI":"10.1016\/S0026-895X(25)13662-6"},{"key":"96483","doi-asserted-by":"crossref","unstructured":"Morinobu S, Tanaka T, Kawakatsu S, et al.: Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci. 1997; 51(4): 253-257. DOI: 10.1111\/j.1440-1819.1997.tb02593.x.","DOI":"10.1111\/j.1440-1819.1997.tb02593.x"},{"key":"96484","doi-asserted-by":"crossref","unstructured":"Olesen OV, Linnet K: Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology. 1997; 55(5): 235-243. DOI: 10.1159\/000139533.","DOI":"10.1159\/000139533"},{"key":"96485","doi-asserted-by":"crossref","unstructured":"Hicks JK, Sangkuhl K, Swen JJ, et al.: Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017; 102(1): 37-44. DOI: 10.1002\/cpt.597.","DOI":"10.1002\/cpt.597"},{"key":"96486","doi-asserted-by":"crossref","unstructured":"Hiemke C, H\u00e4rtter S: Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000; 85(1): 11-28. DOI: 10.1016\/s0163-7258(99)00048-0.","DOI":"10.1016\/S0163-7258(99)00048-0"},{"key":"96487","doi-asserted-by":"crossref","unstructured":"Hemeryck A, Belpaire FM: Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug\u2013drug interactions: An update. Curr Drug Metab. 2002; 3(1): 13-37. DOI: 10.2174\/1389200023338017.","DOI":"10.2174\/1389200023338017"},{"key":"96488","doi-asserted-by":"crossref","unstructured":"Hesse LM, Venkatakrishnan K, Court MH, et al.: CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants. Drug Metab Dispos. 2000; 28(10): 1176-1183.","DOI":"10.1016\/S0026-895X(24)12046-9"},{"key":"96489","doi-asserted-by":"crossref","unstructured":"Kobayashi K, Chiba K, Yagi T, et al.: Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther. 1997; 280(2): 927-933.","DOI":"10.1016\/S0022-3565(24)36462-6"},{"key":"96490","doi-asserted-by":"crossref","unstructured":"Greenblatt DJ, von Moltke LL, Harmatz JS, et al.: Human cytochromes mediating sertraline biotransformation: Seeking attribution. J Clin Psychopharmacol. 1999; 19(6): 489-493. DOI: 10.1097\/00004714-199912000-00001.","DOI":"10.1097\/00004714-199912000-00001"},{"key":"96491","doi-asserted-by":"crossref","unstructured":"Kobayashi K, Ishizuka T, Shimada N, et al.: Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos. 1999; 27(7): 763-766.","DOI":"10.1016\/S0090-9556(24)15222-1"},{"key":"96492","doi-asserted-by":"crossref","unstructured":"Otton SV, Ball SE, Cheung SW, et al.: Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996; 41(2): 149-156. DOI: 10.1111\/j.1365-2125.1996.tb00173.x.","DOI":"10.1111\/j.1365-2125.1996.tb00173.x"},{"key":"96493","doi-asserted-by":"crossref","unstructured":"Fogelman SM, Schmider J, Venkatakrishnan K, et al.: O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999; 20(5): 480-490. DOI: 10.1016\/S0893-133X(98)00113-4.","DOI":"10.1016\/S0893-133X(98)00113-4"},{"key":"96494","doi-asserted-by":"crossref","unstructured":"Hunziker ME, Suehs BT, Bettinger TL, et al.: Duloxetine hydrochloride: A new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005; 27(8): 1126-1143. DOI: 10.1016\/j.clinthera.2005.08.010.","DOI":"10.1016\/j.clinthera.2005.08.010"},{"key":"96495","doi-asserted-by":"crossref","unstructured":"Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn-Schmiedebergs Arch Pharmacol. 1999; 359(2): 147-151. DOI: 10.1007\/pl00005334.","DOI":"10.1007\/PL00005334"},{"key":"96496","unstructured":"Shin J, Saadabadi A: Trazodone. 2024. Available at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470560\/. Accessed April 22, 2025."},{"key":"96497","doi-asserted-by":"crossref","unstructured":"Wen B, Ma L, Rodrigues AD, et al.: Detection of novel reactive metabolites of trazodone: Evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos. 2008; 36(5): 841-850. DOI: 10.1124\/dmd.107.019471.","DOI":"10.1124\/dmd.107.019471"},{"key":"96498","doi-asserted-by":"crossref","unstructured":"Kudo S, Ishizaki T: Pharmacokinetics of haloperidol: An update. Clin Pharmacokinet. 1999; 37(6): 435-456. DOI: 10.2165\/00003088-199937060-00001.","DOI":"10.2165\/00003088-199937060-00001"},{"key":"96499","unstructured":"Abilify: Aripiprazole\/Abilify prescription information. Available at www.abilify.com. Accessed April 22, 2025."},{"key":"96500","unstructured":"Psychopharmacology Institute: Pharmacokinetics of aripiprazole: Clinical summary. Open Access Artic. 2018. Available at https:\/\/psychopharmacologyinstitute.com\/publication\/pharmacokinetics-of-aripiprazole-clinical-summary-2118. Accessed April 22, 2025."},{"key":"96501","unstructured":"Khan I, Kahwaji C: Cyclobenzaprine. 2023. Available at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513362\/. Accessed April 22, 2025."},{"key":"96502","doi-asserted-by":"crossref","unstructured":"Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996; 24(7): 786-791.","DOI":"10.1016\/S0090-9556(25)07430-6"},{"key":"96503","doi-asserted-by":"crossref","unstructured":"Simao A, Antunes M, Marques H, et al.: Amphetamine in biological specimens: Impact and implications for public health. In Handbook of Substance Misuse and Addictions. Switzerland: Springer Nature, 2022: 1-25. DOI: 10.1007\/978-3-030-67928-6_104-1.","DOI":"10.1007\/978-3-030-67928-6_104-1"},{"key":"96504","doi-asserted-by":"crossref","unstructured":"Lucas C, Galettis P, Schneider J: The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018; 84: 2477-2482. DOI: 10.1111\/bcp.13710.","DOI":"10.1111\/bcp.13710"},{"key":"96505","unstructured":"Krock K, Nickley J, Tran K, et al.: Correlation of fentanyl positive drug screens with other medications in patients from pain, rehabilitation and behavioral programs. Ann Clin Lab Sci. 2020; 50(2): 260-265."},{"key":"96506","doi-asserted-by":"crossref","unstructured":"Hedges L: Distribution theory for glass\u2019s estimator of effect size and related estimators. J Educ Stat. 1981; 6(2): 107-128. DOI: 10.2307\/1164588.","DOI":"10.3102\/10769986006002107"},{"key":"96507","doi-asserted-by":"crossref","unstructured":"Durlak JA: How to select, calculate, and interpret effect sizes. J Pediatr Psychol. 2009; 34(9): 917-928. DOI: 10.1093\/jpepsy\/jsp004.","DOI":"10.1093\/jpepsy\/jsp004"},{"key":"96508","doi-asserted-by":"crossref","unstructured":"Cohen J: A power primer. Psychol Bull. 1992; 112(1): 155-159. DOI: 10.1037\/0033-2909.112.1.155.","DOI":"10.1037\/\/0033-2909.112.1.155"},{"key":"96509","unstructured":"Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Mahwah: L. Erlbaum Associates, 1988."},{"key":"96510","unstructured":"RStudio Team: Rstudio: Integrated Development Environment for R. Boston, MA: RStudio, PBC, 2020. Available at http:\/\/www.rstudio.com. Accessed September 21, 2024."},{"key":"96511","unstructured":"RCore Team: The R project for statistical computing. Available at https:\/\/www.R-project.org\/. 2024. Accessed September 21, 2024."},{"key":"96512","doi-asserted-by":"crossref","unstructured":"Sullivan GM, Feinn R: Using effect size-or why the P value is not enough. J Grad Med Educ. 2012; 4(3): 279-282. DOI: 10.4300\/JGME-D-12-00156.1.","DOI":"10.4300\/JGME-D-12-00156.1"},{"key":"96513","doi-asserted-by":"crossref","unstructured":"Su P, Coutts RT, Baker GB, et al.: Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. Xenobiotica. 1993; 23(11): 1289-1298. DOI: 10.3109\/00498259309059439.","DOI":"10.3109\/00498259309059439"},{"key":"96514","doi-asserted-by":"crossref","unstructured":"Aranow AB, Hudson JI, Pope HG, et al.: Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry. 1989; 146(7): 911-913. DOI: 10.1176\/ajp.146.7.911.","DOI":"10.1176\/ajp.146.7.911"},{"key":"96515","doi-asserted-by":"crossref","unstructured":"Westermeyer J: Fluoxetine-induced tricyclic toxicity: Extent and duration. J Clin Pharmacol. 1991; 31(4): 388-392. DOI: 10.1002\/j.1552-4604.1991.tb03723.x.","DOI":"10.1002\/j.1552-4604.1991.tb03723.x"},{"key":"96516","doi-asserted-by":"crossref","unstructured":"Bergstrom RF, Peyton AL, Lemberger L: Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992; 51(3): 239-248. DOI: 10.1038\/clpt.1992.18.","DOI":"10.1038\/clpt.1992.18"},{"key":"96517","doi-asserted-by":"crossref","unstructured":"Preskorn SH, Alderman J, Chung M, et al.: Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994; 14(2): 90-98.","DOI":"10.1097\/00004714-199404000-00002"},{"key":"96518","doi-asserted-by":"crossref","unstructured":"Br\u00f8sen K, Hansen JG, Nielsen KK, et al.: Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol. 1993; 44(4): 349-355. DOI: 10.1007\/BF00316471.","DOI":"10.1007\/BF00316471"},{"key":"96519","doi-asserted-by":"crossref","unstructured":"Alderman J, Preskorn SH, Greenblatt DJ, et al.: Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol. 1997; 17(4): 284-291. DOI: 10.1097\/00004714-199708000-00008.","DOI":"10.1097\/00004714-199708000-00008"},{"key":"96520","unstructured":"GlaxoSmithKline: Product Information: Zyban (Bupropion Hydrochloride) Sustained Release Tablets. Res Triangle Park, NC: GlaxoSmithKline, 2004."},{"key":"96521","doi-asserted-by":"crossref","unstructured":"Weintraub D: Nortriptyline toxicity secondary to interaction with bupropion sustained-release. Depress Anxiety. 2001; 13(1): 50-52. DOI: 10.1002\/1520-6394(2001)13:1<50::aidda8>3.0.co;2-3.","DOI":"10.1002\/1520-6394(2001)13:1<50::AID-DA8>3.0.CO;2-3"},{"key":"96522","doi-asserted-by":"crossref","unstructured":"Hirota N, Ito K, Iwatsubo T, et al.: In vitro\/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos. 2001; 22(2): 53-71. DOI: 10.1002\/bdd.261.","DOI":"10.1002\/bdd.261"},{"key":"96523","unstructured":"Allqvist A: The role of CYP3A4\/5 in alprazolam metabolism. 2010. Available at https:\/\/api.semanticscholar.org\/CorpusID:46604972. Accessed April 22, 2025."},{"key":"96524","doi-asserted-by":"crossref","unstructured":"Greenblatt DJ, von Moltke LL, Schmider J, et al.: Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: In vitro and in vivo studies. J Clin Pharmacol. 1996; 36(9): 792-798. DOI: 10.1002\/j.1552-4604.1996.tb04252.x.","DOI":"10.1002\/j.1552-4604.1996.tb04252.x"},{"key":"96525","unstructured":"Yanagihara Y, Kariya S, Ohtani M, et al.: Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2001; 29(6): 887-890."},{"key":"96526","doi-asserted-by":"crossref","unstructured":"Owen JR, Nemeroff CB: New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety. 1998; 7(Suppl. 1): 24-32.","DOI":"10.1002\/(SICI)1520-6394(1998)7:1+<24::AID-DA7>3.0.CO;2-F"},{"key":"96527","doi-asserted-by":"crossref","unstructured":"DeVane CL, Donovan JL, Liston HL, et al.: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004; 24(1): 4-10. DOI: 10.1097\/01.jcp.0000104908.75206.26.","DOI":"10.1097\/01.jcp.0000104908.75206.26"},{"key":"96528","unstructured":"Brown CH: Overview of drug\u2013drug interactions with SSRIs. US Pharm. 2008; 33(1): HS-3-HS-19. Available at https:\/\/www.uspharmacist.com\/article\/overview-of-drugdrug-interactionswith-ssris. Accessed April 22, 2025."},{"key":"96529","doi-asserted-by":"crossref","unstructured":"Kemp DE, Canan F, Goldstein BI, et al.: Long-acting risperidone: A review of its role in the treatment of bipolar disorder. Adv Ther. 2009; 26(6): 588-599. DOI: 10.1007\/s12325-009-0039-0.","DOI":"10.1007\/s12325-009-0039-0"},{"key":"96530","doi-asserted-by":"crossref","unstructured":"Veraart JKE, Smith-Apeldoorn SY, Bakker IM, et al.: Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: A systematic review. Int J Neuropsychopharmacol. 2021; 24(10): 808-831. DOI: 10.1093\/ijnp\/pyab039.","DOI":"10.1093\/ijnp\/pyab039"},{"key":"96531","doi-asserted-by":"crossref","unstructured":"Doyle OM, De Simoni S, Schwarz AJ, et al.: Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: A validation using antipsychotic and glutamatergic agents. J Pharmacol Exp Ther. 2013; 345(1): 151-160. DOI: 10.1124\/jpet.112.201665.","DOI":"10.1124\/jpet.112.201665"},{"key":"96532","doi-asserted-by":"crossref","unstructured":"Joules R, Doyle OM, Schwarz AJ, et al.: Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile. Psychopharmacology (Berl). 2015; 232(21-22): 4205-4218. DOI: 10.1007\/s00213-015-3951-9.","DOI":"10.1007\/s00213-015-3951-9"},{"key":"96533","doi-asserted-by":"crossref","unstructured":"Shcherbinin S, Doyle O, Zelaya FO, et al.: Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects. Psychopharmacology (Berl). 2015; 232(21-22): 4191-4204. DOI: 10.1007\/s00213-015-4021-z.","DOI":"10.1007\/s00213-015-4021-z"},{"key":"96534","doi-asserted-by":"crossref","unstructured":"Goff DC, Baldessarini RJ: Drug interactions with antipsychotic agents. J Clin Psychopharmacol. 1993; 13(1): 57-67.","DOI":"10.1097\/00004714-199302000-00008"},{"key":"96535","doi-asserted-by":"crossref","unstructured":"Mihara K, Otani K, Ishida M, et al.: Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol. Ther Drug Monit. 1997; 19(1): 43-45. DOI: 10.1097\/00007691-199702000-00007.","DOI":"10.1097\/00007691-199702000-00007"},{"key":"96536","doi-asserted-by":"crossref","unstructured":"Shin JG, Kane K, Flockhart DA: Potent inhibition of CYP2D6 by haloperidol metabolites: Stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol. 2001; 51(1): 45-52. DOI: 10.1046\/j.1365-2125.2001.01313.x.","DOI":"10.1046\/j.1365-2125.2001.01313.x"},{"key":"96537","doi-asserted-by":"crossref","unstructured":"Van Nimmen NFJ, Poels KLC, Menten JJ, et al.: Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care. J Clin Pharmacol. 2010; 50(6): 667-678. DOI: 10.1177\/0091270009347872.","DOI":"10.1177\/0091270009347872"},{"key":"96538","doi-asserted-by":"crossref","unstructured":"Morita T, Shishido H, Tei Y, et al.: Neuroleptic malignant syndrome after haloperidol and fentanyl infusion in a patient with cancer with severe mineral imbalance. J Palliat Med. 2004; 7(6): 861-864. DOI: 10.1089\/jpm.2004.7.861.","DOI":"10.1089\/jpm.2004.7.861"},{"key":"96539","doi-asserted-by":"crossref","unstructured":"Iribarne C, Berthou F, Baird S, et al.: Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996; 9(2): 365-373. DOI: 10.1021\/tx950116m.","DOI":"10.1021\/tx950116m"},{"key":"96540","unstructured":"Moody DE, Alburges ME, Parker RJ, et al.: The involvement of cytochrome P450 3A4 in the N-demethylation of L-alphaacetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos. 1997; 25(12): 1347-1353."},{"key":"96541","doi-asserted-by":"crossref","unstructured":"Iribarne C, Picart D, Dr\u00e9ano Y, et al.: Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997; 60(22): 1953-1964. DOI: 10.1016\/s0024-3205(97)00160-4.","DOI":"10.1016\/S0024-3205(97)00160-4"},{"key":"96542","doi-asserted-by":"crossref","unstructured":"Gerber JG, Rhodes RJ, Gal J: Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004; 16(1): 36-44. DOI: 10.1002\/chir.10303.","DOI":"10.1002\/chir.10303"},{"key":"96543","doi-asserted-by":"crossref","unstructured":"Chang Y, Moody DE, McCance-Katz EF: Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos. 2006; 34(3): 440-448. DOI: 10.1124\/dmd.105.006148.","DOI":"10.1124\/dmd.105.006148"},{"key":"96544","doi-asserted-by":"crossref","unstructured":"Baumann P: Pharmacokinetic\u2013pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996; 31(6): 444-469. DOI: 10.2165\/00003088-199631060-00004.","DOI":"10.2165\/00003088-199631060-00004"},{"key":"96545","doi-asserted-by":"crossref","unstructured":"Hamilton SP, Nunes EV, Janal M, et al.: The effect of sertraline on methadone plasma levels in methadonemaintenance patients. Am J Addict. 2000; 9(1): 63-69. DOI: 10.1080\/10550490050172236.","DOI":"10.1080\/10550490050172236"},{"key":"96546","doi-asserted-by":"crossref","unstructured":"McCance-Katz EF, Sullivan LE, Nallani S: Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict. 2010; 19(1): 4-16. DOI: 10.1111\/j.1521-0391.2009.00005.x.","DOI":"10.1111\/j.1521-0391.2009.00005.x"},{"key":"96547","doi-asserted-by":"crossref","unstructured":"Bertschy G, Eap CB, Powell K, et al.: Fluoxetine addition to methadone in addicts: Pharmacokinetic aspects. Ther Drug Monit. 1996; 18(5): 570-572. DOI: 10.1097\/00007691-199610000-00008.","DOI":"10.1097\/00007691-199610000-00008"},{"key":"96548","doi-asserted-by":"crossref","unstructured":"Batki SL, Manfredi LB, Jacob P, et al.: Fluoxetine for cocaine dependence in methadone maintenance: Quantitative plasma and urine cocaine\/benzoylecgonine concentrations. J Clin Psychopharmacol. 1993; 13(4): 243-250.","DOI":"10.1097\/00004714-199308000-00003"},{"key":"96549","doi-asserted-by":"crossref","unstructured":"Vorspan F, Ksouda K, Bloch V, et al.: A case report of transient but clinically relevant interaction between methadone and duloxetine: A reply to McCance-Katz et al. Am J Addict. 2010; 19(5): 458-459. DOI: 10.1111\/j.1521-0391.2010.00062.x.","DOI":"10.1111\/j.1521-0391.2010.00062.x"},{"key":"96550","doi-asserted-by":"crossref","unstructured":"Grimm S, Stams K, Bui K: In vitro prediction of potential metabolic drug interactions for seroquel. Schizophr Res. 1997; 24(1-2): 198. Available at https:\/\/search-ebscohost-com.proxy2.cl.msu.edu\/login.aspx?direct=true&db=edswss&AN=A1997WP19600560&site=eds-live. Accessed April 27, 2025.","DOI":"10.1016\/S0920-9964(97)82567-4"},{"key":"96551","doi-asserted-by":"crossref","unstructured":"Bakken GV, Molden E, Knutsen K, et al.: Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos. 2012; 40(9): 1778-1784. DOI: 10.1124\/dmd.112.045237.","DOI":"10.1124\/dmd.112.045237"},{"key":"96552","doi-asserted-by":"crossref","unstructured":"Terlinden R, Ossig J, Fliegert F, et al.: Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2007; 32(3): 163-169. DOI: 10.1007\/BF03190478.","DOI":"10.1007\/BF03190478"},{"key":"96553","unstructured":"Thomson PDR: Physicians\u2019 Desk Reference 2010. 64th ed. Montvale, NJ: Thomson PDR, 2010."},{"key":"96554","doi-asserted-by":"crossref","unstructured":"Kneip C, Terlinden R, Beier H, et al.: Investigations into the drug\u2013drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008; 2(1): 67-75. DOI: 10.2174\/187231208783478434.","DOI":"10.2174\/187231208783478434"},{"key":"96555","doi-asserted-by":"crossref","unstructured":"Wade WE, Spruill WJ: Tapentadol hydrochloride: A centrally acting oral analgesic. Clin Ther. 2009; 31(12): 2804-2818. DOI: 10.1016\/j.clinthera.2009.12.003.","DOI":"10.1016\/j.clinthera.2009.12.003"},{"key":"96556","doi-asserted-by":"crossref","unstructured":"Hartrick CT, Rozek RJ: Tapentadol in pain management: A \u03bc-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs. 2011; 25(5): 359-370. DOI: 10.2165\/11589080-000000000-00000.","DOI":"10.2165\/11589080-000000000-00000"},{"key":"96557","doi-asserted-by":"crossref","unstructured":"Pergolizzi J, Alegre C, Blake D, et al.: Current considerations for the treatment of severe chronic pain: The potential for tapentadol. Pain Pract. 2012; 12(4): 290-306. DOI: 10.1111\/j.1533-2500.2011.00487.x.","DOI":"10.1111\/j.1533-2500.2011.00487.x"},{"key":"96558","doi-asserted-by":"crossref","unstructured":"Baron EP, Lucas P, Eades J, et al.: Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018; 19(1): 37. DOI: 10.1186\/s10194-018-0862-2.","DOI":"10.1186\/s10194-018-0862-2"},{"key":"96559","doi-asserted-by":"crossref","unstructured":"Luz-Veiga M, Azevedo-Silva J, Fernandes JC: Beyond pain relief: A review on cannabidiol potential in medical therapies. Pharm Basel Switz. 2023; 16(2): 155. DOI: 10.3390\/ph16020155.","DOI":"10.3390\/ph16020155"},{"key":"96560","doi-asserted-by":"crossref","unstructured":"Doohan PT, Oldfield LD, Arnold JC, et al.: Cannabinoid interactions with cytochrome P450 drug metabolism: A full-spectrum characterization. AAPS J. 2021; 23(4): 91. DOI: 10.1208\/s12248-021-00616-7.","DOI":"10.1208\/s12248-021-00616-7"},{"key":"96561","doi-asserted-by":"crossref","unstructured":"Bordson SJ, Atayee RS, Ma JD, et al.: Tricyclic antidepressants: Is your patient taking them? Observations on adherence and unreported use using prescriber-reported medication lists and urine drug testing. Pain Med. 2014; 15(3): 355-363. DOI: 10.1111\/pme.12300.","DOI":"10.1111\/pme.12300"}],"container-title":["Journal of Opioid Management"],"original-title":[],"link":[{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3880\/4165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/download\/3880\/4165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T15:16:48Z","timestamp":1753715808000},"score":1,"resource":{"primary":{"URL":"https:\/\/wmpllc.org\/ojs\/index.php\/jom\/article\/view\/3880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":123,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,28]]}},"URL":"https:\/\/doi.org\/10.5055\/jom.0907","relation":{},"ISSN":["1551-7489","1551-7489"],"issn-type":[{"value":"1551-7489","type":"electronic"},{"value":"1551-7489","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}